Literature DB >> 2456975

Plasma alpha-subunit levels during the treatment of pituitary adenomas with the somatostatin analog (SMS 201-995).

G Sassolas1, P Serusclat, B Claustrat, J Trouillas, S Merabet, R Cohen, J C Souquet.   

Abstract

The effect os SMS 201-995 (Sandostatin), a long-acting somatostatin analog, on different types of pituitary adenomas including alpha-subunit elevation is illustrated in this report. Treatment induced a fall in hCG levels in a woman with a pituitary adenoma producing only alpha-subunit. In 3 acromegalic patients, there was only a partial drop in GH and alpha-hCG. The same effect was observed in a woman with menopausal FSH and LH levels. SMS reduced plasma TSH and alpha-hCG in a case of thyrotropic adenoma. Two patients exhibiting FSH- and alpha-hCG-secreting adenomas did not respond to acute administration of SMS 201-995. More patients have to be treated before a definitive statement can be made on the usefulness of somatostatin analogs in the management of different types of pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456975     DOI: 10.1159/000180987

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  3 in total

1.  Follicle stimulating hormone-secreting pituitary adenoma: inappropriate secretion and effect of pulsatile luteinizing hormone releasing hormone analogue (buserelin) administration.

Authors:  S Damjanović; D Micić; V Popović; M Petakov; A Kendereski; M Sumarac; D Manojlović; J Mićić
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

Review 2.  Pituitary tumor diagnosis and treatment.

Authors:  Paul L Penar; David J Nathan; Muriel H Nathan; Afshin Salsali
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

3.  Acute effects of Parlodel-LAR and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma.

Authors:  R Abs; P M Parizel; A Beckers
Journal:  J Endocrinol Invest       Date:  1991-02       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.